FDA approves Leo Pharma's tralokinumab after rejection 8 months ago
Eight months after Leo Pharma's atopic eczema treatment, tralokinumab, was rejected in the US, the FDA gives the Danish firm's drug the thumbs-up. Leo Pharma can now market and sell the drug in the US, which could double the company's size, says Leo Pharma executive Becki Morison.
by ULRICH QUISTGAARD, translated by daniel pedersen
The US Food and Drug Administration (FDA) approves of Leo Pharma's biologic drug, tralokinumab, against atopic eczema in adults, Leo Pharma announce in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma strongly criticizes Danish Medicines Council
For subscribers
